Home/Filings/4/0001209191-10-029120
4//SEC Filing

GALEN PARTNERS IV LP 4

Accession 0001209191-10-029120

CIK 0001254419other

Filed

May 18, 8:00 PM ET

Accepted

May 19, 7:50 PM ET

Size

22.2 KB

Accession

0001209191-10-029120

Insider Transaction Report

Form 4
Period: 2010-05-17
Transactions
  • Sale

    Common Stock

    2010-05-17$24.07/sh16,389$394,4525,689,102 total(indirect: See FN)
  • Sale

    Common Stock

    2010-05-18$24.15/sh14,467$349,3665,674,635 total(indirect: See FN)
Transactions
  • Sale

    Common Stock

    2010-05-17$24.07/sh16,389$394,4525,689,102 total(indirect: See FN)
  • Sale

    Common Stock

    2010-05-18$24.15/sh14,467$349,3665,674,635 total(indirect: See FN)
Transactions
  • Sale

    Common Stock

    2010-05-18$24.15/sh14,467$349,3665,674,635 total(indirect: See FN)
  • Sale

    Common Stock

    2010-05-17$24.07/sh16,389$394,4525,689,102 total(indirect: See FN)
Transactions
  • Sale

    Common Stock

    2010-05-18$24.15/sh14,467$349,3665,674,635 total(indirect: See FN)
  • Sale

    Common Stock

    2010-05-17$24.07/sh16,389$394,4525,689,102 total(indirect: See FN)
CLAUDIUS LLC
10% Owner
Transactions
  • Sale

    Common Stock

    2010-05-17$24.07/sh16,389$394,4525,689,102 total(indirect: See FN)
  • Sale

    Common Stock

    2010-05-18$24.15/sh14,467$349,3665,674,635 total(indirect: See FN)
Transactions
  • Sale

    Common Stock

    2010-05-17$24.07/sh16,389$394,4525,689,102 total(indirect: See FN)
  • Sale

    Common Stock

    2010-05-18$24.15/sh14,467$349,3665,674,635 total(indirect: See FN)
Transactions
  • Sale

    Common Stock

    2010-05-17$24.07/sh16,389$394,4525,689,102 total(indirect: See FN)
  • Sale

    Common Stock

    2010-05-18$24.15/sh14,467$349,3665,674,635 total(indirect: See FN)
Transactions
  • Sale

    Common Stock

    2010-05-17$24.07/sh16,389$394,4525,689,102 total(indirect: See FN)
  • Sale

    Common Stock

    2010-05-18$24.15/sh14,467$349,3665,674,635 total(indirect: See FN)
Footnotes (8)
  • [F1]The sale of shares reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Funds on September 1, 2009
  • [F2]The shares were sold as follows: 2,883 shares by Galen Partners IV, L.P. ("Galen IV"), 229 shares by Galen Partners International IV, L.P. ("Galen International IV"), 4 shares by Galen Employee Fund IV, L.P. ("Employee Fund IV"), 12,132 shares by Galen Partners III, L.P. ("Galen III"), 1,099 shares by Galen Partners International III, L.P. ("Galen International III") and 42 shares by Galen Employee Fund III, L.P. ("Employee Fund III" and, collectively with Galen IV, Galen International IV, Employee Fund IV, Galen III, Galen International III, the "Funds").
  • [F3]The shares were sold at prices between $24.06 and $24.15. The Reporting Entities will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
  • [F4]The shares are held as follows: 1,000,082 by Galen IV, 79,444 by Galen International IV, 1,393 by Employee Fund IV, 4,208,640 by Galen III, 381,415 by Galen International III and 18,128 by Employee Fund III. Claudius IV, L.L.C. ("Cladius IV") serves as the sole General Partner of Galen IV and Galen International IV and has sole voting and investment control over the shares held by such funds and may be deemed to beneficially own the shares held by such funds. Wesson Enterprises, Inc. serves as the sole General Partner of Employee Fund IV and Employee Fund III and has sole voting and investment control over the shares held by such funds and may be deemed to beneficially own the shares held by such funds.
  • [F5]Claudius, L.L.C. serves as the sole General Partner of Galen III and Galen International III and has sole voting and investment control over the shares held by such funds and may be deemed to beneficially own the shares held by such funds. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein, except to the extent of its respective pecuniary interest therein.
  • [F6]The shares were sold as follows: 2,545 shares by Galen IV, 202 shares by Galen International IV, 3 shares by Employee Fund IV, 10,709 shares by Galen III, 971 shares by Galen International III and 37 shares by Employee Fund III.
  • [F7]The shares were sold at prices between $24.06 and $24.30. The Reporting Entities will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
  • [F8]The shares are held as follows: 997,537 by Galen IV, 79,242 by Galen International IV, 1,390 by Employee Fund IV, 4,197,931 by Galen III, 380,444 by Galen International III and 18,091 by Employee Fund III. Claudius IV serves as the sole General Partner of Galen IV and Galen International IV and has sole voting and investment control over the shares held by such funds and may be deemed to beneficially own the shares held by such funds. Wesson Enterprises, Inc. serves as the sole General Partner of Employee Fund IV and Employee Fund III and has sole voting and investment control over the shares held by such funds and may be deemed to beneficially own the shares held by such funds.

Issuer

MEDASSETS INC

CIK 0001254419

Entity typeother

Related Parties

1
  • filerCIK 0001203341

Filing Metadata

Form type
4
Filed
May 18, 8:00 PM ET
Accepted
May 19, 7:50 PM ET
Size
22.2 KB